The objectives of this study are to assess PMNL function in HIV+ patients at different stages of disease over an extended period of time, determine if abnormal PMNL function predisposes patients to bacterial infections, and examine the various factors that may affect PMNL function. In addition, we will examine whether or not defects in PMNL function can be reversed by in vitro exposure to colony-stimulating factors. METHODS: Subjects. HIV-infected patients will be grouped according to CD4+ counts (> 500/mm3, 200-500/mm3, and < 200/mm3) and whether or not they are receiving anti-retroviral therapy. Controls groups will consist of patients at risk for HIV infection with a negative HIV antibody test and healthy volunteers without risk factor for HIV infection. Clinical data, including age, risk factors for HIV infection, staging (CDC, Walter Reed), and the occurrence of bacterial infections will be recorded. PMNL function. PMNLs will be isolated from patients and controls and a battery of function assays performed. Chemotaxis, adherence, aggregation, superoxide production in response to stimuli (f-met-leu-phe, PMA, and opsonized zymosan) in a superoxide dismutase (SOD) inhibitable cytochrome C reduction microassay, phagocytosis, and bacterial killing will be determined for patients and compared to the paired control. Effect of colony-stimulating factors on PMNL function. PMNLs will be preincubated with granulocyte and granulocyte-macrophage colony-stimulating factors (G-CSF, GM-CSF) and tested with the battery of assays described above. Factors associated with abnormal PMNL function. We plan to measure circulating levels of immunoglobulins, fibronectin, PMNL chemoattractants (C5a, leukotriene B4, and platelet activating factor), cytokines that affect PMNL function (TNF, IL-1, and gamma-interferon), and colony- stimulating factors, and correlate levels with PMNL function. Fluorocytometry will be used to detect anti-neutrophil antibodies and the expression of PMNL surface markers that are associated with normal PMNL function. Methods of Analysis. The results of PMNL function tests will be reported as the mean plus/minus standard deviation. The means of groups will be analyzed by the Student's test and ANOVA. The relationship between stage of disease and PMNL function will be analyzed by linear regression and ANOVA. Associations between bacterial infections and PMNL function, anti- retroviral therapy, circulating factors, anti-retroviral therapy, circulating factors, anti-PMNL antibodies, surface markers, and other parameters will be analyzed by multivariate analysis.

Project Start
Project End
Budget Start
Budget End
Support Year
10
Fiscal Year
1996
Total Cost
Indirect Cost
Kelesidis, Theodoros; Tran, Thuy Tien T; Stein, James H et al. (2015) Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s. Clin Infect Dis 61:651-60
Safren, Steven A; Biello, Katie B; Smeaton, Laura et al. (2014) Psychosocial predictors of non-adherence and treatment failure in a large scale multi-national trial of antiretroviral therapy for HIV: data from the ACTG A5175/PEARLS trial. PLoS One 9:e104178
Sacktor, Ned; Miyahara, Sachiko; Evans, Scott et al. (2014) Impact of minocycline on cerebrospinal fluid markers of oxidative stress, neuronal injury, and inflammation in HIV-seropositive individuals with cognitive impairment. J Neurovirol 20:620-6
Hulgan, Todd; Stein, James H; Cotter, Bruno R et al. (2013) Mitochondrial DNA variation and changes in adiponectin and endothelial function in HIV-infected adults after antiretroviral therapy initiation. AIDS Res Hum Retroviruses 29:1293-9
Safren, Steven A; Hendriksen, Ellen S; Smeaton, Laura et al. (2012) Quality of life among individuals with HIV starting antiretroviral therapy in diverse resource-limited areas of the world. AIDS Behav 16:266-77
Sacktor, N; Miyahara, S; Deng, L et al. (2011) Minocycline treatment for HIV-associated cognitive impairment: results from a randomized trial. Neurology 77:1135-42
Achenbach, Chad J; Darin, Kristin M; Murphy, Robert L et al. (2011) Atazanavir/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults. Future Virol 6:157-177
Ribaudo, Heather J; Benson, Constance A; Zheng, Yu et al. (2011) No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. Clin Infect Dis 52:929-40
Imamichi, Hiromi; Degray, Gerald; Asmuth, David M et al. (2011) HIV-1 viruses detected during episodic blips following interleukin-7 administration are similar to the viruses present before and after interleukin-7 therapy. AIDS 25:159-64
Albrecht, Mary; Mukherjee, A Lisa; Tierney, Camlin et al. (2011) A randomized clinical trial evaluating therapeutic drug monitoring (TDM) for protease inhibitor-based regimens in antiretroviral-experienced HIV-infected individuals: week 48 results of the A5146 study. HIV Clin Trials 12:201-14

Showing the most recent 10 out of 87 publications